Business Context and Reporting Period
This Form 8-K Current Report is filed by ImmuCell Corporation (NASDAQ: ICCC) on April 7, 2026. The filing primarily addresses significant changes to the Company's Board of Directors, including the departure of long-serving members and the election of new directors effective April 15, 2026. The Company is incorporated in Delaware and maintains its principal executive offices in Portland, Maine.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. For financial performance data, investors should refer to the Company's Annual Report on Form 10-K filed on March 30, 2026, which is referenced in Item 8.01.
Material Changes Versus Prior Period
The material changes disclosed in this report relate exclusively to corporate governance and personnel:
- Director Departures: Bryan K. Gathagan, Michael F. Brigham, and Bobbi Jo Brockmann tendered their resignations from the Board, effective April 15, 2026.
- Historical Context: Mr. Brigham had served as President and CEO for over 25 years (until November 1, 2025) and as a Director since 1999. Ms. Brockmann had served as a Board member for over 8 years but continues as Vice President of Sales and Marketing.
- Director Elections: The Board elected two new directors to fill the vacancies:
- Gilles Guillemette, DVM: Brings over 30 years of executive experience in animal health therapeutics (Elanco, Bayer, Chewy, etc.). He will Chair the new Strategy & Technology Committee and serve on the Audit Committee.
- Anthony DiMarco, Ph.D.: Brings four decades of scientific leadership in biologics (IDEXX, Abbott Laboratories). He will serve on the Compensation, Nominations, and Strategy & Technology Committees.
Guidance, Outlook, and Management Commentary
The filing does not contain specific financial guidance or forward-looking projections. However, it notes the following:
- Strategic Focus: The appointment of Dr. Guillemette and Dr. DiMarco suggests a strategic emphasis on leveraging deep industry experience in animal health therapeutics, R&D, and global manufacturing.
- Investor Communication: The Company posted an Investor Presentation to its website (Exhibit 99.2) providing an overview of its business and strategy, consistent with the March 30, 2026, 10-K filing.
- Risks and Contingencies: No specific risks or contingencies are detailed in this 8-K, other than the standard transition of board leadership.
Important Facts for Investor Verification
- Verify the effective date of the board changes (April 15, 2026) and the immediate impact on committee compositions.
- Review the referenced Investor Presentation (Exhibit 99.2) and the March 30, 2026, Form 10-K for the most recent financial performance and strategic outlook.
- Confirm the continued role of Bobbi Jo Brockmann as Vice President of Sales and Marketing despite her resignation from the Board.
- Assess the strategic fit of the new directors' backgrounds (veterinary medicine, biologics R&D) with ImmuCell's current product pipeline and market position.